Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Arch Neurol
; 69(2): 262-4, 2012 Feb.
Article
en En
| MEDLINE
| ID: mdl-22332194
ABSTRACT
BACKGROUND:
The oral sphingosine-1-phosphate receptor modulator fingolimod (FTY720) was recently approved for the treatment of relapsing-remitting multiple sclerosis. To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce.OBJECTIVE:
To describe a patient who discontinued fingolimod treatment after a local malignant melanoma was diagnosed. Three months after cessation, he had a striking rebound of multiple sclerosis activity.DESIGN:
Case report and review of literature.SETTING:
Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Munich, Germany. PATIENT A 45-year-old man diagnosed as having relapsing-remitting multiple sclerosis. MAIN OUTCOMEMEASURES:
Multiple sclerosis disease activity including annual relapse rate, Expanded Disability Status Scale score, and number of gadolinium-enhancing lesions on magnetic resonance imaging before, during, and after treatment with fingolimod.RESULTS:
Three months after discontinuation of treatment with fingolimod, the patient experienced a severe relapse, with Expanded Disability Status Scale score progression from 2.5 to 4.5. On brain and spinal magnetic resonance imaging, he showed a rebound of disease activity, with a drastic increase of gadolinium-enhancing lesions (>20).CONCLUSIONS:
Two aspects relevant to any newly approved multiple sclerosis treatment with immunomodulatory properties are highlighted with this case first, possible rebound of disease activity after discontinuation; second, the occurrence of a tumor as a possible treatment-related complication.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Glicoles de Propileno
/
Esfingosina
/
Esclerosis Múltiple Recurrente-Remitente
/
Factores Inmunológicos
/
Melanoma
Idioma:
En
Revista:
Arch Neurol
Año:
2012
Tipo del documento:
Article